China, Merck and HPV
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
M-Trust – which is now in beta test release mode – is described by the company as a "cyber-physical trust platform." ...
Hosted on MSN1d
Truist Securities Downgrades Merck (MRK)Fintel reports that on January 8, 2025, Truist Securities downgraded their outlook for Merck (NYSE:MRK) from Buy to Hold.
EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...
Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress ...
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).
Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...
The winners of ‘Best African Women Researchers Awards’ and ‘Best Young African Researcher Awards’ will be enrolled into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback